Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Women harmed by vaginal laser for treatment of GSM—the latest casualties of fear and confusion surrounding hormone therapy

Kaunitz, Andrew M., MD, FACOG, NCMP1; Pinkerton, JoAnn V., MD, FACOG, NCMP2; Manson, JoAnn E., MD, DrPH, FACP, NCMP3

doi: 10.1097/GME.0000000000001313
Editorial: PDF Only

1Department of Obstetrics & Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL

2The North American Menopause Society, University of Virginia Health System, Charlottesville, VA

3Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Address correspondence to: Andrew M. Kaunitz, MD, FACOG, NCMP, University of Florida Term Professor and Associate Chairman, Department of Obstetrics & Gynecology, University of Florida College of Medicine-Jacksonville. E-mail: Andrew.kaunitz@jax.ufl.edu

Received 14 January, 2019

Revised 14 January, 2019

Accepted 14 January, 2019

Funding/support: None.

Financial disclosure/conflicts of interest: AMK consults with AMAG and Pfizer and previously consulted with Shionogi. Research funding (to University of Florida) from Endoceutics, TherapeuticsMD. The other authors have nothing to disclose.

© 2019 by The North American Menopause Society.